See the source article by following the link below:
An innovative new drug, Evolocumab, can prevent heart attacks and strokes by cutting bad cholesterol to unprecedented levels on a background of statin therapy, in a large randomized, double-blind, placebo-controlled trial involving 27,564 patients published in the NEJM.
An innovative new drug, Evolocumab, can prevent heart attacks and strokes by cutting bad cholesterol to unprecedented levels on a background of statin therapy, in a large randomized, double-blind, placebo-controlled trial involving 27,564 patients published in the NEJM.
No comments:
Post a Comment